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    The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 
3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her 
diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as 
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been 
improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. 
The case has been followed up in detail, and this report is expected to be a useful reference for diabetes care. 
Introduction 
    Diabetes mellitus has been one of the crucial 
diseases from medical and economical points of view 
[1]. It has been prevalent across the world including 
developed countries and also developing countries. 
For adequate glycemic control, there are some diabetic 
standard guidelines [2,3].  
 
    Regarding the therapy of diabetes mellitus, 
nutritional treatment has been the fundamental 
treatment including various dietary methods such as 
calorie restriction (CR), Mediterranean diet, low-
carbohydrate diet (LCD) and so on [4]. LCD was 
initiated by Bernstein and other investigators in the 
North American region [5,6]. Successively in Japan, 
LCD was started and developed by author and 
colleagues so far through the Japan LCD promotion 
association (JLCDPA) [7,8]. 
 
    Regarding the pharmaceutical aspect of diabetes, 
there have been recently several kinds of effective oral 
hyperglycemic agents (OHA). They include α‐
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glucosidase inhibitors, glinides, dipeptidyl peptidase-4 
(DPP-4) inhibitors and Sodium-Glucose 
Cotransporter-2 (SGLT2) inhibitors [9]. In particular, 
DPP-4 inhibitors and SGLT2 inhibitors have been in 
focus for clinical diabetic practice and research [2]. 
 
    On the other hand, a certain relationship between 
type 2 diabetes mellitus (T2DM) and depression has 
been known for various studies [10]. The prevalence 
of depression in T2DM is lower in East Asia and 
higher in the US and Europe [10]. The ratio would be 
10.6% in the US, 9.3% in the UK and 6.1% in China, 
and female cases show higher prevalence than male in 
each country [11-13]. 
 
    T2DM has been suggested to be one of the risk 
factors for depressive state or depression [14]. 
Furthermore, both diabetes and depression have been 
independent risk factors for developing dementia [15]. 
Thus, these three factors would be highly risky for 
brain atrophy with hippocampal atrophy by brain MRI 
[16]. Consequently, it is crucial to prevent 
exacerbation of diabetes and depression. 
 
    Regarding the two topics mentioned above, there 
was a report related to OHA and depression in 
diabetic patients [9]. Among them, the influence of 
the administration of DPP-4 and SGLT2 inhibitors for 
developing depression are shown. These aspects 
would be meaningful for diabetes practice in the 
actual out clinic and primary care setting. 
 
    The authors have continued diabetic research for 
long in several axes [17]. They include a daily profile 
of blood glucose, M value, continuous glucose 
monitoring (CGM), elevated ketone bodies, 
comparison of CR and LCD, elevated ketone bodies in 
fetus-placenta-pregnant woman-newborn, and so on 
[18,19]. During our diabetic practice and research, we 
have an impressive case associated with diabetes and 
depression. Then, we describe the case and some 




    The case was a 55-year-old female patient with 
T2DM. She has diagnosed as a depressive state 5 years 
ago and has received anti-depressant agents. About 3 
years ago, she was pointed out to have diabetes in 
another psychosomatic clinic. At that time, her data 
included moderate obesity, negative anti-GAD 
antibody, and T2DM as a diagnosis.  
 
    After that, her general status including depression 
and diabetes had been stable. Then she hoped to be 




    We have evaluated her diabetes in detail. She has 
slight peripheral neuropathy in the hands and feet, no 
apparent retinopathy and stage 1 nephropathy. 
Regarding physical examination, she showed normal 
vital signs and unremarkable physical status (pulse 76, 
BP 112/77, SpO2 96%), and no consciousness or 
feeling disorders from hyper- or hypoglycemia. She 






    The data of the laboratory tests were in the 
following. The fundamental peripheral blood and 
biochemical data were: WBC 5100 /μL, RBC 4.31 x 
106/μL, Hb 13.6 g/dL, Plt 22.1 x 104/μL, AST 20 IU/mL, 
ALT 30 IU/mL, ALP 197 IU/mL (100-340), LD 158 
IU/mL (100-210), T-Bil 0.5 mg/dL, BUN 14 mg/dL, Cre 
0.8 mg/dL, Uric Acid 5.4 mg/dL, Na 141 mmol/L, K 4.3 
mmol/L, Cl 104 mmol/L, HDL 69 mg/dL, LDL 155 
mg/dL, TG 226mg/dL. Data related diabetes were 
HbA1c 6.7%, pre-prandial glucose 184 mg/dL. Urine 




    From the data mentioned above, we have pointed 
out her medical problems. Her problem lists showed 
that #1 T2DM, #2 dyslipidemia (on anti-dyslipidemia 
agent), #3 metabolic syndrome, #4 osteoarthritis (OA) 
of the bilateral knees, #5 depression (slight). 
 
Clinical Progress: 
    Successively, the same treatment had been 
continued and her HbA1c was stable at around 6.5%. 
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As to the medication, she had been provided 
metformin 1000mg, vildagliptin 100mg and Ezetimibe 
10mg per day as the treatment of T2DM and 
dyslipidemia. 
 
    For the depressive status, she showed rather an 
unstable situation with depression, general malaise 
and sometimes suicide desire for years. She had been 
provided duloxetine hydrochloride (Cymbalta) 20mg 
in the morning as Serotonin and Noradrenaline 
Reuptake Inhibitor (SNRI), mirtazapine (Reflex) 15mg 
before sleep as Noradrenergic and Specific 
Serotonergic Antidepressant (NaSSA), and etizolam 
(Depas) 1.0 – 1.5 mg per day as Benzodiazepine 
anxiolytics. 
 
    Approximately 1 year ago, her HbA1c value was 
suddenly elevated up to 7.9% without any special 
causes detected. Consequently, she was started to 
have Ipragliflozin L-Proline (Sugar) 25 mg as an 
SGLT2 inhibitor. By the administration of SGLT2-I, 
her blood glucose and HbA1c values were decreased to 
a satisfactory degree. The progress of HbA1c value, 
urine sugar and the administration of anti-diabetic 
agents were shown in (Fig-1). HbA1c was reduced 
from 7.9% to 6.4% and urine sugar was increased 
after providing of Ipragliflozin. 
 
    After 1 year from the initiation of Ipragliflozin, lipid 
profile revealed that HDL 65 mg/dL, LDL 110 mg/dL, 
TG 128 mg/dL. Although there was not a quantitative 
evaluation for the degree of her depressive state, 
unstable psychiatric symptoms such as suicide desire 




    In recent diabetic practice, the spread of LCD and 
beneficial effects of SGLT2 inhibitors have been 
attracting attention. In the light of carbohydrates, the 
former is to reduce the intake of carbohydrates, and 
the latter is to increase the excretion of carbohydrates. 
Then, both seem to have a common basis for the 
function of carbohydrates. In this article, we report a 
case of T2DM showing improved glycemic variability 
and depression by the administration of SGLT2 
inhibitors. 
 
    According to the common statement of the 
European Association for the Study of Diabetes (EASD) 
and the American Diabetes Association (ADA), LCD 
has been recommended for the management of 
diabetes [20]. LCD is defined as the diet which reduces 
carbohydrate intake less than 26% of total daily 
energy intake. LCD has been reported to have the 
efficacy of reducing blood glucose in diabetic patients. 
On the other hand, moderate restriction of 
carbohydrates (26-45%) showed no additional effect 
[20]. Also, LCD can reduce the risk for patients with 
metabolic syndrome, in which the values of blood 
          
Fig-1: Clinical course of the case with HbA1c changes and medication 
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glucose, triglyceride and cholesterol have been 
reduced [21]. 
 
    Recent data of the National Health and Nutrition 
Examination Survey (NHANES) were investigated for 
the effect of LCD [22]. There were some impressive 
and equivocal results [20]. The result was that the 
subjects of the lowest quartile for carbohydrate intake 
(39-49% of carbohydrate intake) showed the 50% 
elevated risk for cardio- and cerebro- vascular 
diseases [22]. However, despite the careful nature of 
their analysis [22], the cut-off for the lowest quartile 
of carbohydrates considered as LCD is still higher in 
absolute (200g/day) or relative terms (39–49% of 
total energy intake) compared to common LCDs. The 
archetypical LCD is the ketogenic diet (low 
carbohydrate/high fat), and ketogenic dieters 
consume only 10–30g/day of carbohydrates (10–20% 
of total energy) [21]. 
 
    Other LCDs set a 50g/day carbohydrate intake per 
day, while moderate carbohydrate restriction allows 
up to 80–130g/day (26–45% of total energy) [20,21]. 
Therefore, the interpretation of Mazidi et al. [22] 
should be made with greater caution, since the study 
may underestimate the effect of a true LCD.   
 
    SGLT2 inhibitors have been in focus for their 
beneficial clinical efficacy. There have been some 
mega studies about them as follows: i) Canagliflozin 
and Renal Events in Diabetes with Established 
Nephropathy Clinical Evaluation (CREDENCE) [23], 
ii) Canagliflozin cardioVascular Assessment Study 
(CANVAS) [24], iii) Empagliflozin Cardiovascular 
Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients-Removing Excess Glucose (EMPA-REG 
OUTCOME) study [25] and iv) Dapagliflozin Effect on 
CardiovascuLAR Events (DECLARE) -TIMI 58 [26].  
 
    As to the cardiovascular benefits of SGLT2 
inhibitors, 38,723 patients from 4 trials for 2.9 years 
on average were investigated [27]. As a result, SGLT2 
inhibitors could protect against CVD and death in 
diverse subsets of T2DM patients regardless of the 
CVD history [27]. 
 
    One of the SGLT2 inhibitors would be Ipragliflozin 
L-Proline. It has been rather prevalent and has been 
investigated for its efficacy in some studies. There is a 
STELLA-LONG TERM study, which stands for the 
Specified drug use resulTs survEy of IpragLifLozin 
treAtment in type 2 diabetic patients, LONG-TERM 
[28]. It is a 3-year prospective post-marketing 
surveillance study, which is continuing on the long-
term efficacy and safety of ipragliflozin [29]. Some 
results were reported concerning clinical effects and 
adverse drug reactions (ADRs) [30]. Among them, 
significant reductions were found in HbA1c (− 0.8%), 
fasting plasma glucose (− 31.9 mg/dL), body weight (− 
2.9 kg), in AST (− 9.0 U/L) and ALT (− 14.7 U/L) 
[30]). In a short period, liver function was improved 
in 20.5% (543/2,648) of patients after 3-month of 
ipragliflozin in T2DM patients with abnormal liver 
function [31].  As for the adverse effect of ipragliflozin, 
there was 0.04-0.18% of depression as psychiatric 
disorders, which would be very rare [28]. 
 
    There was also a ASSIGN-K Study for Ipragloflozin 
[32]. ASSIGN-K stands for a study of the safety and 
efficacy of ipragliflozin in the treatment of diabetes in 
Kanagawa. For 301 patients with T2DM followed 104 
weeks, there was the significant reduction of A1c 
(8.07% to 7.24%), fasting blood glucose (-19.8 
mg/dL) and postprandial blood glucose (-29.6 mg/dL). 
In addition, both of body fat (-1.87kg) and fat-free 
mass (-1.02kg) were significantly reduced. 
  
    An experiment of ipragliflozin was found for giving 
a sugar solution to mice [33]. Experiment mice with 
T2DM was classified into 3 groups, in which they were 
fed i) ordinary drinking water, ii) water + glucose 
solution, or iii) water + sucrose solution. As a result, 
effective dose and response to ipragliflozin did not 
significantly differ in 3 groups. Then, anti-diabetic and 
anti-obesity effects of ipragliflozin were not greatly 
affected by sugar solution intake. Consequently, these 
results suggest that ipragliflozin would be an effective 
agent for T2DM patients, who take excessive intake of 
carbohydrates [33]. 
 
    Depression has been one of the important 
complications of diabetes. In order to investigate the 
relationship between LCD and mental status, T2DM 
cases were assessed by a questionnaire for taking food 
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and by the depression, anxiety, and stress scale [34]. 
As a result, cases in the highest quartile of LCD score 
showed a 69% lower risk of poor sleep, and a 73% 
lower risk of anxiety compared with those in the 
lowest quartile. Consequently, T2DM patients with 
LCD meals seem to have better sleep conditions and 
less mental disorders [34].  
 
    There was a study of the association between 
depression in diabetes and treatment types (insulin 
and/or OHA) [36]. For diabetic patients of 
50,774/48,978 (M/F), male subjects showed more 
depression of significantly higher odds ratio (OR) 1.27 
in insulin, OR 1.41 in insulin and OHA, compared to 
those in only OHA treatment. Female showed a 
similar tendency, but there were no significant 
differences with OR 1.17 and 1.35, respectively. Thus, 
the influence of treatment type to depression seemed 
to be more in male than in female diabetic patients 
[35].   
 
    The risk of depression in diabetes was studied 
depending on different OHA [9]. T2DM subjects 
(n=40,214) were divided into 2 groups. Dep. group 
has depression (n=1979), and the cont. group has no 
depression (n=38,235). The adjusted odds ratio (AOR) 
of the dep. group was 1.39 for female and 1.18 for 
lower for HbA1c. Between two groups, there was no 
significant difference in α-alpha-glucosidase 
inhibitors, thiazolidinediones or glinides. In contrast, 
there was a significant difference (numbers of dep. 
group vs cont. group) in sulfonylureas (112 vs 3404), 
DPP-4 inhibitors (54 vs 3731), and SGLT-2 inhibitors 
(1 vs 378), respectively [9]. Thus, SGLT-2 inhibitors 
seem to have anti-depression efficacy for diabetic 
patients.   
 
    The case reported in this article has several 
distinctive features. They included i) depression was 
present formerly, ii) developed T2DM in the course, 
iii) worsened diabetic control without apparent 
triggers, iv) starting of SGLT2 inhibitor Ipragliflozin, 
v) improvement in glycemic response and depression. 
At that time, there were no other changes in the 
diabetic situation or medical agents. Therefore, clinical 
improvement seemed to be at least in part due to the 
effect of Ipragliflozin. As the limitation of this study, 
all relevant factors have not been known or 
investigated. 
 
    In summary, an impressive diabetic case was 
described in this article. Administration of Ipragliflozin 
to T2DM with depression has improved glycemic 
control and depression. The case has been followed up 
at present and in the future, and various possible 
factors will be investigated. This report may become a 
useful reference for diabetes care. 
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